At a time when the vaccination campaign against Covid-19 has begun in many countries of the world, the World Health Organization (WHO) announced, this Thursday, January 7, that the poorest countries will begin to receive their first doses of vaccinations between the end of January and the middle of February.
The Covax program has made agreements to acquire two billion doses of vaccines and the first will begin arriving in the coming weeks, said WHO vaccines official Kate O’Brien.
The international Covax program, launched by WHO with the support of the “Alliance for Vaccines” (Gavi), aims to help ensure equitable access to future Covid-19 vaccines. Covax aims to provide sufficient doses to vaccinate 20% of the population in each of the participating countries before the end of the year.
Asked about the date that low-income African countries could benefit from these vaccines, Kate O’Brien noted during a WHO online debate that Covax “had access to more than two billion doses of vaccines.” “We will start distributing these vaccines probably at the end of January or otherwise, certainly early to mid February“, she added.
A “vast vaccine repository” soon to be approved?
The WHO granted its first emergency approval on Thursday, December 31, since the start of the Covid-19 pandemic Pfizer-BioNTech vaccine, which makes it easier for countries to use the vaccine quickly.
According to the WHO, 63 candidate vaccines have already been tested in humans and 21 of them have reached the final stage of massive testing.. Additionally, 172 other candidate vaccines have been developed in the laboratory for further human testing.
“There really is a large stock of vaccines“Potentials, which the WHO is studying for possible approval in the coming months,” said the vaccine manager, adding that 15 manufacturers had already contacted WHO proposing to mass-produce the doses.
However, it is premature to predict how long vaccinated people it would be immune to Covid-19, he said. Regarding the new virus variants, initially detected in the UK or South Africa, he said there was no evidence that current vaccines were not effective, and these vaccines can be adapted if necessary to these variants.